BRAF抑制剂治疗患者中非感染性葡萄膜炎实际发生率:全国性临床队列研究
该韩国全国性回顾性队列研究纳入77,323例皮肤黑色素瘤或肺癌患者,比较BRAF抑制剂暴露组(n=396)、免疫检查点抑制剂(ICI)暴露组(n=22,474)和传统细胞毒性化疗未暴露组(n=54,453)的1年非感染性葡萄膜炎累积发生率。结果显示BRAF抑制剂组葡萄膜炎风险显著高于未暴露组和ICI组,作者强调治疗前应告知患者相关风险以便及时眼科评估。
要点
- BRAF抑制剂组1年葡萄膜炎累积发生率为2.27%,未暴露组0.33%,ICI组0.35%。
- 校正后BRAF抑制剂组较未暴露组葡萄膜炎风险aHR为7.52,较ICI组aHR为5.68。
- 倾向评分匹配后BRAF抑制剂组较未暴露组葡萄膜炎aHR为35.51,重度葡萄膜炎aHR为15.80。
核心结论
- 接受BRAF抑制剂治疗的黑色素瘤或肺癌患者非感染性葡萄膜炎风险显著高于传统细胞毒性药物或ICI治疗者。
- 作者认为这些发现强调治疗前对患者进行BRAF抑制剂相关葡萄膜炎风险教育的重要性,以便在用药期间出现症状时及时进行眼科评估和治疗。
研究设计与样本
- 全国性基于人群的回顾性临床队列研究,数据来自韩国健康保险审查评价院数据库。
- 共纳入77,323例接受BRAF抑制剂(n=396)、ICI(n=22,474)或传统细胞毒性化疗(n=54,453)的皮肤黑色素瘤或肺癌患者。
主要发现
- 治疗启动后第一年,未暴露组、ICI暴露组和BRAF抑制剂暴露组葡萄膜炎累积发生率分别为0.33%、0.35%和2.27%。
- 校正后BRAF抑制剂暴露组较未暴露组葡萄膜炎风险aHR为7.52(95%CI 3.83-14.75,P<.001),较ICI暴露组aHR为5.68(95%CI 2.81-11.47,P<.001)。
- 1:4倾向评分匹配后,BRAF抑制剂暴露组较未暴露组葡萄膜炎aHR为35.51(95%CI 4.49-280.48,P=.001),重度葡萄膜炎aHR为15.80(95%CI 1.76-141.00,P=.014)。
- BRAF抑制剂暴露组内交叉分析显示,指数日期后1年较指数日期前1年葡萄膜炎风险增加3.71倍(95%CI 1.03-13.40,P=.046)。
- BRAF抑制剂暴露组中,女性、慢性肾脏病和黑色素瘤与葡萄膜炎风险增加趋势相关,但未达统计学显著。
临床怎么用
- 作者认为治疗前应就BRAF抑制剂相关葡萄膜炎风险对患者进行教育,以便用药期间出现症状时及时进行眼科评估和治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the incidence of noninfectious uveitis in skin melanoma or lung cancer patients who received BRAF inhibitors with that in those who received immune checkpoint inhibitors (ICIs) or conventional cytotoxic chemotherapy. DESIGN: Nationwide population-based retrospective clinical cohort study METHODS: From the Health Insurance Review and Assessment Service database of South Korea, we retrospectively defined 77,323 patients with skin melanoma or lung cancer who received BRAF inhibitor therapy (BRAF inhibitor-exposed group; n = 396), ICIs (ICI-exposed group; n = 22,474), or conventional cytotoxic chemotherapy (unexposed group; n = 54,453). We calculated the 1-year cumulative incidence of noninfectious uveitis in each group from the first day of BRAF inhibitor, ICI, or cytotoxic agent administration. RESULTS: During the first year of treatment initiation, the cumulative incidence of uveitis was 0.33%, 0.35%, and 2.27% in the unexposed, ICI-exposed, and BRAF inhibitor-exposed groups, respectively. Adjusted hazard ratios (aHR) indicated a 7.52-fold and 5.68-fold increased risk of uveitis in the BRAF inhibitor-exposed group compared with that in the unexposed and ICI-exposed groups (95% confidence interval [CI] 3.83-14.75, P < .001 and 95% CI 2.81-11.47, P < .001, respectively). After 1:4 propensity score matching, aHRs showed a 35.51-fold and 15.80-fold increased risk (95% CI 4.49-280.48, P = .001 and 95% CI 1.76-141.00, P = .014) of uveitis and severe uveitis, respectively, in the BRAF inhibitor-exposed versus unexposed patients. Crossover analysis within the BRAF inhibitor-exposed group showed a 3.71-fold increase in uveitis risk during 1-year post index date in comparison with 1-year prior to index date (95% CI 1.03-13.40, P = .046). In the BRAF inhibitor-exposed group, female sex, chronic kidney disease, and melanoma were associated with a trend of increased, albeit nonsignificant, risk of uveitis. CONCLUSIONS: Melanoma or lung cancer patients treated with BRAF inhibitors showed significantly higher risk of noninfectious uveitis than patients treated with conventional cytotoxic drugs or ICIs. These findings emphasize the importance of pretreatment patient education on BRAF-inhibitor-associated uveitis risk to enable prompt ophthalmic evaluation and treatment if symptoms arise during drug administration.
引用
- Jung H, Kim S, Lee CS, et al. Real-World Incidence of Incident Noninfectious Uveitis in Patients Treated With BRAF Inhibitors: A Nationwide Clinical Cohort Study. Am J Ophthalmol. 2024. PMID: 38977151. doi:10.1016/j.ajo.2024.07.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。